Braveheart Bio upsized IPO pricing
Analysis based on 10 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026
The successful pricing of Braveheart Bio's upsized IPO signals strong investor demand for clinical-stage biopharmaceutical companies, potentially boosting sentiment in the sector. The offering is expected to provide significant capital for Braveheart Bio's development programs, while the underwriters will earn fees from the transaction.
Braveheart Bio, a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy, announced the pricing of its upsized initial public offering of 21,250,000 shares at $18.00 per share, expected to raise gross proceeds of $382.5 million. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol BRVE, with the offering expected to close on August 7, 2026. The underwriters have a 30-day option to purchase up to an additional 3,187,500 shares. Goldman Sachs, Jefferies, Toronto-Dominion Bank — TD Cowen, Stifel, and Cantor are acting as joint book-running managers. The SEC declared the registration statement effective on August 5, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard